Clinical Trials Browser

Phase 4 × Hodgkin Disease × Brentuximab Vedotin × Clear all

Hodgkin Disease, Recurrence

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma